Liquidia closes $75M PIPE, draws $25M debt facility, files counterclaims in UTHR patent suit

Liquidia Corp

Closed private placement of 7.18M shares at $10.442/share for ~$75M gross proceeds; additional $25M drawn under revenue interest financing amendment.
Filed response to UTHR patent suit seeking dismissal of invalidated '793 patent claims and asserting counterclaims that '327 patent is invalid due to undisclosed prior art.
Enrolled first PH-ILD patient in YUTREPIA ASCENT study; PDUFA date for tentative approval is Jan 24, 2024.
FDA agreed that single Phase 3 trial of L606 in PH-ILD will support both PAH and PH-ILD indications; global study to start later in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.